BioSig Technologies Inc Stock Price, News & Analysis

BioSig Technologies (NASDAQ: BSGM) has announced the pricing of a public offering of up to 4,666,667 shares of common stock at $0.75 per share, expected to raise approximately $3.5 million in gross proceeds. The offering is scheduled to close on June 28, 2022, subject to customary conditions. BioSig plans to utilize the net proceeds for commercialization of the PURE EP™ System, organizational development, and general corporate purposes. The company operates under SEC regulations following the effective shelf registration statement filed earlier.

BioSig Technologies, Inc. (Nasdaq: BSGM) announced its intention to conduct an underwritten public offering of common stock. The company aims to use the proceeds for commercialization of the PURE EP™ System, organizational development, working capital, and general corporate purposes. Laidlaw & Company (UK) Ltd. is the sole book-running manager for this offering. The offering remains subject to market conditions, and no completion assurances are provided. A shelf registration statement was previously filed and declared effective in January 2021.

BioSig Technologies, Inc. (NASDAQ: BSGM) announced a 60-day evaluation agreement with Cleveland Clinic for its PURE EP(TM) System, enhancing electrophysiology by improving intracardiac signal fidelity. The evaluation follows the induction of a new commercialization team and aligns with the company's national rollout strategy. Over 75 physicians have utilized this technology in over 2500 patient cases, indicating significant clinical interest. The PURE EP(TM) System demonstrated a 75% improvement in signal quality according to a recently published multi-center study.

BioSig Technologies (NASDAQ: BSGM) announced its national commercial launch of the PURE EP™ System, set for July 1, 2022. The company has over 30 advanced leads at Medical Centers of Excellence and has streamlined product evaluations from 180-360 days to just 60 days. The PURE EP™ System, a non-invasive class II device, enhances cardiac electrophysiology with significant clinical backing: over 2,200 patient cases and a 75% improvement in signal quality. BioSig's efforts are led by Chief Commercial Officer Gray Fleming, with a partnership established to facilitate financing options for prospective buyers.

BioSig Technologies will showcase its flagship PURE EP System at the upcoming EPLive conference in Austin, Texas, on June 2-3, 2022. This event attracts leading electrophysiologists and offers insights into treating complex cardiac arrhythmias. The Company’s enhanced NOVA-5 Software promises greater signal processing capabilities. To date, over 2,200 patient cases have been recorded using the PURE EP System, showcasing a 75% improvement in signal quality over conventional methods according to recent clinical studies.

BioSig Technologies (BSGM) has made significant advancements in its PURE EP(TM) system, achieving over 2,200 patient cases and engaging 75 physicians across 17 hospitals. The company has strengthened its management with the addition of industry veteran Gray Fleming as CCO to enhance commercialization strategies. Noteworthy updates include the rollout of a new software, NOVA-5, and a two-phase purchasing approach for the PURE EP system. BioSig is positioned in a promising $12.2 billion global electrophysiology market, with no debt reported, showcasing a solid foundation for growth.

BioSig Technologies (NASDAQ: BSGM) will exhibit at Heart Rhythm 2022 from April 29 to May 1, 2022 in San Francisco. The company will showcase its PURE EP(TM) Nova-5 Software, enhancing electrophysiology with better signal fidelity. A poster presentation will highlight clinical data on Dynamic Algorithmic Notch Filtering, co-authored by noted physicians. BioSig's system, with FDA 510(k) clearance, has seen 75 physicians complete over 2,200 patient cases, demonstrating a 75% improvement in signal quality according to study results.

BioSig Technologies, Inc. (NASDAQ: BSGM) announced that CEO Kenneth L. Londoner will present at the NobleCon18 on April 20, 2022, in Hollywood, Florida. Attendees can meet BioSig management during breakout sessions. A high-definition video webcast of the presentation will be available the following day. The PURE EP™ System, an FDA-cleared device, has been used in over 2,200 cases by 75 physicians, showing a 75% improvement in intracardiac signal quality. Clinical data is published in the Journal of Cardiovascular Electrophysiology.

BioSig Technologies (Nasdaq: BSGM) announced a partnership with Summit Blue Capital to implement a leasing and finance program for its PURE EP™ System, enhancing purchase flexibility for U.S. hospitals. This collaboration aims to expedite the system's entry into new electrophysiology labs, improving commercial plans and facilitating upfront payments per installation. The FDA-cleared PURE EP™ device has successfully been used in over 2,150 patient cases. Clinical studies show a 75% improvement in signal quality compared to traditional methods.